Rectal Cancer - Non-operative Management

This episode details the revolutionary Watch and Wait (WW) strategy, the most significant paradigm shift in modern rectal cancer care. We distinguish PCR (Pathological Complete Response, post-surgical) from CCR (Clinical Complete Response, the goal for organ preservation), and discuss how Total Neoadjuvant Therapy (TNT) maximizes the CCR rate. The primary motivation for WW is avoiding the guaranteed morbidity of proctectomy, particularly the debilitating effects of Low Anterior Resection Syndrome (LARS).WW safety hinges on strict adherence to a triodality assessment (DR, endoscopy, and MRI). CCR status requires MRI to show a low signal scar (MRTG1) with a complete absence of restricted diffusion on DWI (Diffusion Weighted Imaging). Patients must understand the trade-off: accepting a 25% risk of local regrowth within the first two years, managed by intensive surveillance.Crucially, outcomes demonstrate WW is oncologically safe, offering statistically similar Overall Survival (OS) compared to radical surgery. The risk of local regrowth is balanced by a high (nearly 90%) success rate for salvage resection if regrowth is caught early. The episode concludes by looking at the future role of genomic profiling (like the DNA repair deregulation score) and functional testing (patient-derived organoids) to proactively predict non-responders and avoid unnecessary radiation morbidity.